Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2. / Reekie, Joanne; Stovring, Henrik; Nielsen, Henrik; Johansen, Isik S.; Benfield, Thomas; Wiese, Lothar; Stærke, Nina Breinholt; Iversen, Kasper; Mustafa, Ahmed Basim; Petersen, Kristine Toft; Juhl, Maria Ruwald; Knudsen, Lene Surland; Iversen, Mette Brouw; Andersen, Sidsel Dahl; Larsen, Fredrikke Dam; Baerends, Eva Anna Marianne; Lindvig, Susan Olaf; Rasmussen, Line Dahlerup; Madsen, Lone Wulff; Bannister, Wendy; Jensen, Tomas Oestergaard; Dietz, Lisa Loksø; Ostrowski, Sisse Rye; Østergaard, Lars; Tolstrup, Martin; Lundgren, Jens D.; Søgaard, Ole Schmeltz; ENFORCE Study Group.
I: International Journal of Infectious Diseases, Bind 146, 107111, 2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2
AU - Reekie, Joanne
AU - Stovring, Henrik
AU - Nielsen, Henrik
AU - Johansen, Isik S.
AU - Benfield, Thomas
AU - Wiese, Lothar
AU - Stærke, Nina Breinholt
AU - Iversen, Kasper
AU - Mustafa, Ahmed Basim
AU - Petersen, Kristine Toft
AU - Juhl, Maria Ruwald
AU - Knudsen, Lene Surland
AU - Iversen, Mette Brouw
AU - Andersen, Sidsel Dahl
AU - Larsen, Fredrikke Dam
AU - Baerends, Eva Anna Marianne
AU - Lindvig, Susan Olaf
AU - Rasmussen, Line Dahlerup
AU - Madsen, Lone Wulff
AU - Bannister, Wendy
AU - Jensen, Tomas Oestergaard
AU - Dietz, Lisa Loksø
AU - Ostrowski, Sisse Rye
AU - Østergaard, Lars
AU - Tolstrup, Martin
AU - Lundgren, Jens D.
AU - Søgaard, Ole Schmeltz
AU - ENFORCE Study Group
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024
Y1 - 2024
N2 - Objectives: This study aimed to compare antibody trajectories among individuals with SARS-CoV-2 hybrid and vaccine-induced immunity. Methods: Danish adults receiving three doses of BTN162b2 or mRNA-1237 were included prior to first vaccination (Day 0). SARS-CoV-2 anti-spike IgG levels were assessed before each vaccine dose, at Day 90, Day 180, 28 days after 3rd vaccination (Day 251), Day 365, and prior to 4th vaccination (Day 535). SARS-CoV-2 PCR results were extracted from the national microbiology database. Mixed-effect multivariable linear regression investigated the impact of hybrid-immunity (stratified into 4 groups: no hybrid immunity, PCR+ prior to 3rd dose, PCR+ after 3rd dose and before Day 365, PCR+ after Day 365) on anti-spike IgG trajectories. Results: A total of 4,936 individuals were included, 47% developed hybrid-immunity. Anti-spike IgG increases were observed in all groups at Day 251, with the highest levels in those PCR+ prior to 3rd dose (Geometric Mean; 535,647AU/mL vs. 374,665AU/mL with no hybrid-immunity, P<0.0001). Further increases were observed in participants who developed hybrid immunity after their 3rd dose. Anti-spike IgG levels declined from Day 251-535 in individuals without hybrid-immunity and in those who developed hybrid-immunity prior to their 3rd dose, with lower rate of decline in those with hybrid-immunity. Conclusion: Hybrid-immunity results in higher and more durable antibody trajectories in vaccinated individuals.
AB - Objectives: This study aimed to compare antibody trajectories among individuals with SARS-CoV-2 hybrid and vaccine-induced immunity. Methods: Danish adults receiving three doses of BTN162b2 or mRNA-1237 were included prior to first vaccination (Day 0). SARS-CoV-2 anti-spike IgG levels were assessed before each vaccine dose, at Day 90, Day 180, 28 days after 3rd vaccination (Day 251), Day 365, and prior to 4th vaccination (Day 535). SARS-CoV-2 PCR results were extracted from the national microbiology database. Mixed-effect multivariable linear regression investigated the impact of hybrid-immunity (stratified into 4 groups: no hybrid immunity, PCR+ prior to 3rd dose, PCR+ after 3rd dose and before Day 365, PCR+ after Day 365) on anti-spike IgG trajectories. Results: A total of 4,936 individuals were included, 47% developed hybrid-immunity. Anti-spike IgG increases were observed in all groups at Day 251, with the highest levels in those PCR+ prior to 3rd dose (Geometric Mean; 535,647AU/mL vs. 374,665AU/mL with no hybrid-immunity, P<0.0001). Further increases were observed in participants who developed hybrid immunity after their 3rd dose. Anti-spike IgG levels declined from Day 251-535 in individuals without hybrid-immunity and in those who developed hybrid-immunity prior to their 3rd dose, with lower rate of decline in those with hybrid-immunity. Conclusion: Hybrid-immunity results in higher and more durable antibody trajectories in vaccinated individuals.
KW - Anti-spike IgG
KW - Hybrid immunity
KW - SARS-CoV-2
KW - Vaccines
U2 - 10.1016/j.ijid.2024.107111
DO - 10.1016/j.ijid.2024.107111
M3 - Journal article
C2 - 38801970
AN - SCOPUS:85196316682
VL - 146
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
M1 - 107111
ER -
ID: 395872291